Cargando…

Lupus community panel proposals for optimising clinical trials: 2018

Formidable impediments stand in the way of treatment development for lupus. These include the unwieldy size of current trials, international competition for scarce patients, complex outcome measures and a poor understanding of these outcomes in the world at large. The heterogeneity of the disease it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merrill, Joan T, Manzi, Susan, Aranow, Cynthia, Askenase, Anca, Bruce, Ian, Chakravarty, Eliza, Chong, Ben, Costenbader, Karen, Dall’Era, Maria, Ginzler, Ellen, Hanrahan, Leslie, Kalunian, Ken, Merola, Joseph, Raymond, Sandra, Rovin, Brad, Saxena, Amit, Werth, Victoria P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894527/ https://www.ncbi.nlm.nih.gov/pubmed/29657738 http://dx.doi.org/10.1136/lupus-2018-000258

Ejemplares similares

Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints
por: Almaani, Salem, et al.
Publicado: (2020)

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial
por: Tamirou, Farah, et al.
Publicado: (2015)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
por: Gomez Mendez, Liliana Michelle, et al.
Publicado: (2019)

Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project
por: Manzi, Susan, et al.
Publicado: (2019)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
por: Yazdany, Jinoos, et al.
Publicado: (2014)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Preliminary population-based incidence and prevalence estimates of systemic lupus erythematosus: the California Lupus Surveillance Project
por: Dall'Era, Maria C, et al.
Publicado: (2014)

The Impact of Telemedicine on Rheumatology Care
por: Tang, Wei, et al.
Publicado: (2022)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research
por: Tse, Karin, et al.
Publicado: (2021)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

A glimpse into the future of systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2022)

Association of Sweet's Syndrome and Systemic Lupus Erythematosus
por: Barton, J. L., et al.
Publicado: (2011)

Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer
por: Glass, Allison S., et al.
Publicado: (2018)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Defining the Optimal Management Strategy for Small Renal Masses
por: Dall’Era, Marc, et al.
Publicado: (2021)

Correction: Lupus community panel proposals for optimising clinical trials: 2018
Publicado: (2018)

A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
por: Rovin, Brad H., et al.
Publicado: (2016)

Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations
por: Wu, Jennifer N., et al.
Publicado: (2010)

Lupus spectrum ambiguity has long-term negative implications for patients
por: Bruce, Ian N, et al.
Publicado: (2023)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective
por: Buie, Joy, et al.
Publicado: (2023)

Lymphoma risk in systemic lupus: effects of treatment versus disease activity
por: Clarke, AE, et al.
Publicado: (2012)

Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity
por: Askanase, Anca D., et al.
Publicado: (2019)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus
por: Katz, Patricia, et al.
Publicado: (2019)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons — California, 2007–2017
por: Gianfrancesco, Milena A., et al.
Publicado: (2021)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

Active surveillance for prostate cancer
por: Dall’Era, Marc A., et al.
Publicado: (2018)

A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2021)

Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries
por: Izmirly, Peter M, et al.
Publicado: (2021)

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
por: Schwartz, Noa, et al.
Publicado: (2009)

Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria
por: van Vollenhoven, Ronald, et al.
Publicado: (2022)

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort
por: Urowitz, M B, et al.
Publicado: (2016)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kbv1u76gr898p3hca71g9vd1ht